Navigation Links
BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
Date:5/18/2011

LYNBROOK, N.Y., May 18, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that there will be three separate presentations on collagenase clostridium histolyticum (trademarked XIAPEX® in Europe) for the treatment of patients suffering from Dupuytren's contracture at the upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting to be held in Oslo, Norway at the Oslo Congress Centre on May 26-28, 2011.

The presentations will take place as follows:

Friday, May 27th, 2011, 2:24 PM CEST (8:24 AM EDT)
Location: Hall A, OPS 140 / A-0287
Session 13: Dupuytren's
Presentation Title: Efficacy and tolerability of collagenase clostridium histolyticum in European patients with Dupuytren's contracture: Results from a multicenter, open-label study
Presenters: J. Witthaut, S. Wilbrand, R. Milner, C. Bainbridge, D.E. Boyce, H. Kushner, R.A. Gerber, P. Szczypa (Sweden)

Friday, May 27th, 2011, 2:32 PM CEST (8:32 AM EDT)
Location: Hall A, OPS 141 / A-0292
Session 13: Dupuytren's
Presentation Title: Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: Mechanism of action and tissue effects
Presenters: P. Szczypa, R. Gerber, FTD Kaplan, A. Cole, SGE Hart (UK)

Friday, May 27th, 2011, 2:40 PM CEST (8:40 AM EDT)
Location: Hall A, OPS 142 / A-0299
Session 13: Dupuytren's
Presentation Title: Efficacy and safety of collagenase clostridium histolyticum (CCH) in patients who had previous hand surgery
Presenters: C. Bainbridge, RA Gerber, P. Szczypa, B Cohen, M-P Hellio Le Graverand (UK)

About Collagenase

Collagenase is an enzyme that breaks down collagen and is the only protease that can hydrolyze the triple helical region of collagen under physiological conditions. The specific substrate collagen comprises approximately one-third of the total protein in mammalian organisms, and it is the main constituent of skin, tendon and cartilage, as well as the organic component of teeth and bone. The body relies on endogenous collagenase production to remove dead tissue, and collagenase production is an essential biological mechanism that regulates matrix remodeling and the normal turnover of tissue. The Clostridial collagenase produced by BioSpecifics has a broad specificity towards all types of collagen and is acknowledged as much more efficient than mammalian collagenases. Clostridial collagenase cleaves the collagen molecule at multiple sites along the triple helix, whereas the mammalian collagenase is only able to cleave the molecule at a single site along the triple helix. Because collagenase does not damage the cell membrane, it is widely used for cell dispersion for tissue disassociation and cell culture.

There are a number of medical conditions that can result from an excess accumulation of collagen. Collagenase offers a minimally invasive treatment option for patients and can be administered in an office setting. It holds considerable therapeutic potential to change the way patients are treated for a variety of diseases and indications.

About F.E.S.S.H.

The Federation of European Societies for Surgery of the Hand (F.E.S.S.H.) is an organization which represents national hand surgery societies in Europe. Its object is to improve the standard of hand surgery throughout Europe. It seeks to develop surgical resources by advising European authorities of the requirements and appropriate quality of hand care.

The purpose of F.E.S.S.H. is to rationalize and unify the training and educational structure for qualification of European hand surgery specialists. The standard would be the amount and level of knowledge approved for the specialty of hand surgery within Europe.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in Europe and has announced European regulatory approval and the first commercial sale in the United Kingdom. Asahi Kasei Pharma Corporation is responsible for marketing XIAFLEX® in Japan. More information about BioSpecifics Technologies Corp. may be found on its website at www.biospecifics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding BioSpecifics' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by BioSpecifics and by its partner Auxilium regarding progress toward achievement of Auxilium's objectives for the US launch of XIAFLEX® for Dupuytren's contracture; the ability of Pfizer to achieve its objectives for XIAPEX® in Europe; the ability of Asahi Kasei to achieve its objectives for XIAFLEX® in Japan; the success of the Phase 3 trials for XIAFLEX for the treatment of Peyronie's disease; the outcome of the dispute with Auxilium over the Company's right to conduct clinical trials; the Company's ability to restart the Chien-803 trial for injectable collagenase for the treatment of canine lipomas and the clinical success of that trial; the Company's ability to initiate and complete clinical trials in additional indications, all of which will determine the amount of milestone, royalty and sublicense income BioSpecifics may receive; and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2010 and its reports on Form 8-K filed with the SEC. All forward-looking statements included in this press release are made as of the date hereof, and the Company assumes no obligation to update these forward-looking statements.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... RoviSys, ... services based in Aurora, Ohio, has broken ground on a new building in ... Triangle Park area, this new location solidifies a commitment to business in the ...
(Date:5/20/2016)... ... , ... Kablooe Design, a leading provider of product design and development services ... the business. “We have worked hard to build long-term relationships,” says President and CEO, ... honor of serving their product design and development needs through the years.” , Kablooe ...
(Date:5/19/2016)... RIDGE, British Columbia , May 19, 2016 ... AdvanTec Global Innovations Inc. (AGI), based out of ... recently added Greenlane Biogas Ltd. to its existing ... 2-year contract manufacturing agreement. AFS along with its ... Technologies (ABT) is a vertically integrated industrial group ...
(Date:5/19/2016)... May 19, 2016 - I ... orale durante il 52 ° ...    - Le conclusioni dello studio indicano ... pazienti trattati, di cui il 90% presenta una d ... o più. Il settantadue per cento dei pazienti ha riscontrato ...
Breaking Biology Technology:
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... YORK , March 9, 2016 This ... and future states of the RNA Sequencing (RNA Seq) ... segments such as instruments, tools and reagents, data analysis, ... Analyze various segments of the RNA-Sequencing market such as ... services Identify the main factors affecting each segment and ...
Breaking Biology News(10 mins):